Skip to main content

Drug Interactions between magaldrate and Spectracef

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

magaldrate cefditoren

Applies to: magaldrate and Spectracef (cefditoren)

GENERALLY AVOID: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil. According to the manufacturer, a dose of an antacid containing magnesium hydroxide (800 mg) and aluminum hydroxide (900 mg) reduced the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of a single dose of cefditoren pivoxil (400 mg, administered following a meal) by 14% and 11%, respectively. The clinical significance of these alterations is unknown.

MANAGEMENT: The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).

References

  1. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):

Switch to consumer interaction data

Drug and food interactions

Moderate

cefditoren food

Applies to: Spectracef (cefditoren)

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of cefditoren pivoxil. According to the manufacturer, administration of cefditoren pivoxil following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 50% and 70%, respectively, compared to administration in the fasting state. The absolute bioavailability of cefditoren pivoxil is approximately 14% under fasting conditions and 16% when given with a low-fat meal.

MANAGEMENT: To ensure maximal oral absorption, cefditoren pivoxil should be administered with or immediately after a meal.

References

  1. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc (2001):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer